WordNet

not in agreement or harmony; "views discordant with present-day ideas"
lacking in harmony (同)disharmonious, dissonant, inharmonic
a neoplasm of lymph tissue that is usually malignant; one of the four major types of cancer

PrepTutorEJDIC

一致しない,調和しない / (音が)不協和の,耳ざわりな

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 濾胞性リンパ腫における組織学的進展 histologic transformation of follicular lymphoma

English Journal

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances.

Cabillic F1, Gros A, Dugay F, Begueret H, Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D, Corre R, Lespagnol A, Soler G, Dagher J, Catros V, Le Calve M, Merlio JP, Belaud-Rotureau MA.Author information 1*Université de Rennes 1, Faculté de Médecine, Rennes, France; †Inserm, UMR991, Liver Metabolisms and Cancer, Rennes, France; ‡Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, Rennes, France; §Service de Biologie des Tumeurs, CHU de Bordeaux, Bordeaux, France; ‖UMR CNRS 6290, IFR 140, Rennes, France; ¶Service de Pathologie, CHU de Bordeaux, Pessac, France; #Service d'Anatomie et Cytologie Pathologiques, CHU de Rennes, Rennes, France; **Service de Pneumologie, CHU de Rennes, Rennes, France; and ††Service de Génétique Moléculaire et de Génomique Médicale, CHU de Rennes, Rennes, France.AbstractINTRODUCTION: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs). Crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK-positive advanced-stage NSCLC. Fluorescent in situ hybridization (FISH) has been established in clinical trials as the standard procedure method for detecting ALK rearrangements. Although the detection of ALK by immunohistochemistry (IHC) has been proposed for the screening of patients, large-scale studies are warranted to validate such a hierarchical approach.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.J Thorac Oncol.2014 Mar;9(3):295-306. doi: 10.1097/JTO.0000000000000072.
INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs). Crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK-positive advanced-stage NSCLC. Fluorescent in situ hybridization (FISH) has been e
PMID 24518086

Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms.

Seegmiller AC1, Wasserman A, Kim AS, Kressin MK, Marx ER, Zutter MM, Mosse CA.Author information 1Department of Pathology, Microbiology, and Immunology.AbstractAbstract Fluorescence in situ hybridization for abnormalities common to myelodysplastic syndrome (MDS FISH) is often used with traditional karyotype in the diagnosis and monitoring of myeloid neoplasms. However, its value in these roles has been questioned. To evaluate its utility, we compared MDS FISH results with karyotype in 544 bone marrow specimens obtained for diagnosis (180 cases) or follow-up (364 cases) of myeloid neoplasia. We found excellent concordance between FISH and karyotype, such that FISH is rarely abnormal (1.7% at diagnosis and 3.0% at follow-up) in cases with normal karyotype. Even in the rare discordant cases, the abnormal FISH has little or no clinical value. Thus, we propose that this test should be limited to cases with inadequate karyotype only. Such guidelines could result in significant cost savings with no impact on patient diagnosis.
Leukemia & lymphoma.Leuk Lymphoma.2014 Mar;55(3):601-5. doi: 10.3109/10428194.2013.801470. Epub 2013 Aug 28.
Abstract Fluorescence in situ hybridization for abnormalities common to myelodysplastic syndrome (MDS FISH) is often used with traditional karyotype in the diagnosis and monitoring of myeloid neoplasms. However, its value in these roles has been questioned. To evaluate its utility, we compared MDS F
PMID 23876099

Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell-apheresis product: implications for clinical decisions and impact on patient treatment.

Liwski CJ1, Padley DJ, Gustafson MP, Winters JL, Gastineau DA, Jacob EK.Author information 1Division of Transfusion Medicine, Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.AbstractCASE REPORT: A 50-year-old male with T-cell lymphoma presented for autologous peripheral blood stem cell transplantation. After granulocyte-colony-stimulating factor (G-CSF) mobilization, his peripheral blood CD34+ cell count was 166 × 10(6) /L on the day before collection, which predicted a high yield of CD34+ cells in the apheresis product. The first two collections had yields much lower than expected, triggering an investigation and changes to the apheresis collection methods since mobilization appeared adequate from the peripheral CD34+ values.
Transfusion.Transfusion.2014 Mar;54(3):541-4. doi: 10.1111/trf.12324. Epub 2013 Jun 30.
CASE REPORT: A 50-year-old male with T-cell lymphoma presented for autologous peripheral blood stem cell transplantation. After granulocyte-colony-stimulating factor (G-CSF) mobilization, his peripheral blood CD34+ cell count was 166 × 10(6) /L on the day before collection, which predicted a hi
PMID 23808629

Japanese Journal

Discordant lymphocyte-depketed classical Hodgkin's and peripheral T-cell lymphoma arising in a patient 11 years after deagnosis of multicentric Castleman's disease

PARK Joonhong,LEE Ji Eun,KIM Myungshin,LIM Jihyang,KIM Yonggoo,HAN Kyungja,PARK Gyeongsin,JUNG Young Hee,ROH Sang Young,HONG Young Seon
International journal of hematology 98(1), 114-121, 2013-07-01
NAID 10031189604

Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma.

Nakatani Koya,Nakamoto Yuji,Watanabe Kenichiro,Saga Tsuneo,Higashi Tatsuya,Togashi Kaori
Clinical nuclear medicine 37(7), 656-662, 2012-07
… [Purpose]: The usefulness of 18F fluorodeoxyglucose (FDG) positron emission tomography (PET) in pediatric Hodgkin lymphoma (p-HL) has been well demonstrated; … however, pediatric non-Hodgkin lymphoma (p-NHL) has distinct characteristics from p-HL and adult NHL. … In group B, PET diagnoses were concordant with CIM in 21 and discordant in 11 studies. … Of the discordant cases, PET suggested remnant lesions in 5 cases, whereas CIM suggested lesions in 6 cases. …
NAID 120005307068